Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02516657 · ClinicalTrials.gov registry record · Phase 3

Liraglutide in Adolescents With Type 1 Diabetes

A Phase 3 study of Type 1 Diabetes, sponsored by University at Buffalo.

Completed
Registry status
Phase 3
Development phase
5
Enrollment target
1
Study location

NCT02516657: Completed Phase 3 study of Type 1 Diabetes, sponsored by University at Buffalo.

NCT02516657 is a Phase 3 study of Type 1 Diabetes that has completed, run by University at Buffalo. The registered enrollment target is 5 participants, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02516657, a Phase 3 study of Type 1 Diabetes, has completed, sponsored by University at Buffalo.

COMPLETED
Registry status
Phase 3
Development phase
5 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to study the effect of a liraglutide, a glucagon-like peptide agonist, on post-meal blood glucose concentrations, glucagon levels, mean weekly blood sugars, and insulin doses in adolescents with Type 1 diabetes. Type 1 diabetes is an autoimmune disease that is usually diagnosed before the age of 20. Individuals with this disease are completely dependent on insulin for survival. While significant advances have been made in technological support for improving diabetes control, insulin remains the only effective treatment for Type 1 diabetes. Liraglutide is a long-acting glucagon-like peptide-1 analog. This drug is approved for the treatment of Type 2 diabetes in adults. This study will test the effect of liraglutide on blood sugar control in adolescents with Type 1 diabetes.

Primary Outcome

The primary outcome is to determine whether liraglutide decreases mean weekly blood glucose (mean mg/dL glucose as measured by continuous glucose monitor readings) in adolescents with Type 1 diabetes

Conditions Studied

Type 1 Diabetes

Interventions

  • DRUG Liraglutide

Study Locations (1)

New York

  • UBMD Pediatrics, Division of Pediatric Endocrinology - Buffalo

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2012-05
Est. Completion 2023-08-03
Phase Phase 3
University at Buffalo

67 total trials

What the finished NCT02516657 record still lists

NCT02516657 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 767-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Liraglutide is the first listed.

NCT02516657 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT02516657 about?

NCT02516657 is a clinical study titled "Liraglutide in Adolescents With Type 1 Diabetes". The purpose of this study is to study the effect of a liraglutide, a glucagon-like peptide agonist, on post-meal blood glucose concentrations, glucagon levels, mean weekly blood sugars, and insulin doses in adolescents with Type 1 diabetes. Type 1 diabetes is an autoimmune disease that is usually di...

What is the current status of trial NCT02516657?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 5 participants. The study started on 2012-05. Estimated completion is 2023-08-03.

What conditions does trial NCT02516657 study?

This clinical trial studies the following conditions: Type 1 Diabetes.

What interventions are being tested in trial NCT02516657?

The interventions under investigation include: Liraglutide (DRUG).

Who is sponsoring clinical trial NCT02516657?

This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02516657 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 1 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02516657's enrollment target sits among peer trials

5 198th of 198 higher than 1 of 198 other Type 1 Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02516657, the US trial registry maintained by the National Library of Medicine. NCT02516657 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.